213 related articles for article (PubMed ID: 23358406)
1. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
[TBL] [Abstract][Full Text] [Related]
2. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
3. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
6. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
7. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
Fisher DR; Shen S; Meredith RF
J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
[TBL] [Abstract][Full Text] [Related]
8. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Arrichiello C; Aloj L; Mormile M; D'Ambrosio L; Frigeri F; Caracò C; Arcamone M; De Martinis F; Pinto A; Lastoria S
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):956-66. PubMed ID: 22237846
[TBL] [Abstract][Full Text] [Related]
12. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
14. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
Hindorf C; Lindén O; Stenberg L; Tennvall J; Strand SE
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):4003S-6S. PubMed ID: 14506200
[TBL] [Abstract][Full Text] [Related]
15. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
16. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
Ferrer L; Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Le Gouill S; Wegener WA; Goldenberg DM; Bardiès M
Cancer; 2010 Feb; 116(4 Suppl):1093-100. PubMed ID: 20127958
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
[TBL] [Abstract][Full Text] [Related]
18. Anthropometric approaches and their uncertainties to assigning computational phantoms to individual patients in pediatric dosimetry studies.
Whalen S; Lee C; Williams JL; Bolch WE
Phys Med Biol; 2008 Jan; 53(2):453-71. PubMed ID: 18184999
[TBL] [Abstract][Full Text] [Related]
19. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
